PBF-999, the first in class treatment in development for the Prader-Willi Syndrome has received “Orphan Drug Designation” by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA)

by Palobiofarma

2 months ago
Prader-Willi Syndrome, PBF-99

The Orphan Drug Designation indicates the acknowledgement by the Regulatory Authorities of USA and the EU that PBF-999 have the potential to address the specific needs of individuals suffering from Pr...

Palobiofarma Receives Rare Pediatric Disease Designation from the U.S. FDA for PBF-999 for the Treatment of Prader-Willi Syndrome

by Palobiofarma

6 months ago
Palobiofarma, Rare Pediatric Disease (RPD) Designation, FDA, Prader-Willi Syndrome

Palobiofarma has announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s phosphodiesterase 10 (PDE-10) inhibitor, PBF-999, f...